Giles Campion, a pharmaceutical industry veteran, has been appointed head of research and development and chief medical officer at Silence Therapeutics Plc, effective 1 June. In this role he will help manage the company’s early-stage portfolio of RNA interference (RNAi) medicines. Dr Campion was chief medical officer at Prosensa Holding NV, a specialist in oligonucleotide therapeutics which was acquired by BioMarin Pharmaceuticals Inc in 2015. Most recently, he was chief medical officer for Albumedix Ltd, a spin-out of Novozymes A/S specialising in recombinant albumin-based products. Dr Campion holds a medical degree and doctorate from Bristol University in the UK.
Silence Therapeutics announced the appointment on 16 April 2019.
Copyright 2019 Evernow Publishing Ltd.